The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma

Hahn, Andrew W.; Lebenthal, Justin; Genovese, Giannicola; Sircar, Kanishka; Tannir, Nizar M.; Msaouel, Pavlos

doi:10.1016/j.ctarc.2022.100640

Cited by 15 publications

(13 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This hypothesis is supported by the observation of significant tumor shrinkage in the treated groups compared with the placebo, right from the first ultrasound evaluation. Moreover, the intrinsic sensitivity of the tumor response to anti-angiogenic treatments was not predictable, and we hypothesize that the model used here with these human ccRCCs was particularly sensitive to axitinib, probably as a function of the histo-pathological particularities of these RCCs and the characteristics of the parental tumors [37].…”

Section: Discussionmentioning

confidence: 93%

BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model

Courcier,

Leguerney,

Benatsou

et al. 2023

IJMS

View full text Add to dashboard Cite

Standard imaging cannot reliably predict the nature of renal tumors. Among malignant renal tumors, clear cell renal cell carcinoma (ccRCC) is the most common histological subtype, in which the vascular endothelial growth factor 2 (VEGFR-2) is highly expressed in the vascular endothelium. BR55, a contrast agent for ultrasound imaging, consists of gas-core lipid microbubbles that specifically target and bind to the extracellular portion of the VEGFR-2. The specific information provided by ultrasound molecular imaging (USMI) using BR55 was compared with the vascular tumor expression of the VEGFR-2 by immunohistochemical (IHC) staining in a preclinical model of ccRCC. Patients’ ccRCCs were orthotopically grafted onto Nod-Scid-Gamma (NSG) mice to generate patient-derived xenografts (PdX). Mice were divided into four groups to receive either vehicle or axitinib an amount of 2, 7.5 or 15 mg/kg twice daily. Perfusion parameters and the BR55 ultrasound contrast signal on PdX renal tumors were analyzed at D0, D1, D3, D7 and D11, and compared with IHC staining for the VEGFR-2 and CD34. Significant Pearson correlation coefficients were observed between the area under the curve (AUC) and the CD34 (0.84, p < 10−4), and between the VEGFR-2-specific signal obtained by USMI and IHC (0.72, p < 10−4). USMI with BR55 could provide instant, quantitative information on tumor VEGFR-2 expression to characterize renal masses non-invasively.

show abstract

Section: Discussionmentioning

confidence: 93%

BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model

Courcier,

Leguerney,

Benatsou

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Albeit metastasectomy is still recommended whenever possible, 8 average 6‐month survival rate in CM is still under 50% 3 . Therapies specifically intended for metastatic RCC include nephrectomy, radiotherapy, immunotherapy, and tyrosine kinase inhibitors 5,9 …”

Section: Discussionmentioning

confidence: 99%

Cutaneous metastasis of a sarcomatoid–rhabdoid renal tumor to a distal phalanx

Feito‐Sancho,

Rubio‐Flores,

Lorido‐Cortés

et al. 2023

Int J Dermatology

View full text Add to dashboard Cite

“…Sarcomatoid dedifferentiation is known to have a weak response to tyrosine kinase inhibitor monotherapy. However, immune checkpoint therapy combinations have shown remarkable responses, with nivolumab-plus-ipilimumab being the best option [118].…”

Section: Rcc With Sarcomatoid Featuresmentioning

confidence: 99%

Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma

Baston,

Parosanu,

Stanciu

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The management of renal cell carcinoma (RCC) has been revolutionized over the past two decades with several practice-changing treatments. Treatment for RCC often requires a multimodal approach: Local treatment, such as surgery or ablation, is typically recommended for patients with localized tumors, while stage IV cancers often require both local and systemic therapy. The treatment of advanced RCC heavily relies on immunotherapy and targeted therapy, which are highly contingent upon histological subtypes. Despite years of research on biomarkers for RCC, the standard of care is to choose systemic therapy based on the risk profile according to the International Metastatic RCC Database Consortium and Memorial Sloan Kettering Cancer Centre models. However, many questions still need to be answered. Should we consider metastatic sites when deciding on treatment options for metastatic RCC? How do we choose between dual immunotherapy and combinations of immunotherapy and tyrosine kinase inhibitors? This review article aims to answer these unresolved questions surrounding the concept of personalized medicine.

show abstract

The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma

Cited by 15 publications

References 75 publications

BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model

BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model

Cutaneous metastasis of a sarcomatoid–rhabdoid renal tumor to a distal phalanx

Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma

Contact Info

Product

Resources

About